
Promontory Therapeutics Inc.: A clinical-stage pharma company innovating small molecule immunotherapies.
Promontory Therapeutics Inc. is a clinical-stage pharmaceutical company founded with the mission to innovate in the field of small molecule immunotherapies. The company's vision is to address unmet medical needs in oncology by developing novel anti-cancer agents. Their lead candidate, PT-112, is a highly potent immunogenic cell death (ICD) inducer currently in Phase clinical development. Promontory Therapeutics focuses on creating therapies that exhibit unique mechanisms of action, single-agent activity, and demonstrated safety.
Promontory Therapeutics has garnered attention in the biotech community, being nominated for the Prix Galien USA Best Startup. The company has made significant strides in advancing its lead candidate through clinical trials, showcasing its potential to revolutionize cancer treatment. With a dedicated team of experts and support from notable investors, Promontory Therapeutics continues to make impactful contributions to the field of oncology, aiming to provide new hope for patients with challenging cancer diagnoses.

Promiliad Biopharma

PTC Therapeutics
ptcbio.com

Starton Therapeutics

Promentis Pharmaceuticals
Promakhos Therapeutics
promakhos.com

Checkpoint Therapeutics
checkpointtx.com

LTZ Therapeutics

Xios Therapeutics

PNP Therapeutics

Dual Therapeutics

Pheast Therapeutics
pheast.com

Pinpoint Therapeutics

Nirogy Therapeutics

NextPoint Therapeutics
nextpointtx.com

Ostentus Therapeutics
Companies similar to Promontory Therapeutics include Promiliad Biopharma, PTC Therapeutics, Starton Therapeutics and Promentis Pharmaceuticals.
Promontory Therapeutics was founded in 2010.
Promontory Therapeutics' headquarters is located in New York City, NY, US.
Promontory Therapeutics' most recent funding round was for $37M (USD) in December 2021.
As of Dec 14, 2021, Promontory Therapeutics has raised a total of $72M (USD).
Promontory Therapeutics has 26 employees as of Feb 4, 2024.